NCT05538624: A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
- State
- Stopped early
- Phase
- Phase 1 and Phase 2
- People
- 14 taking part
- Started
- 9 Dec 2022
- Primary completion
- 1 Apr 2024
- Arms
- Part 1 escalating AVB-001 between 0.6 and 3.6 ug hIL-2/kg/day; and Part 2 AVB-001 at the MTD/RP2D
- Results
- None posted
- 14 Sep 2022: Trial registered
- 9 Dec 2022: Trial started
- 10 Apr 2024: Trial terminated